share_log

GSK(GSK.US)“美泊利珠单抗”在华获批新适应症

GSK (GSK.US) "Mubilizumab" has been approved for a new indication in China.

Zhitong Finance ·  Jan 2 21:22

Chronic sinusitis accompanied by nasal polyps is a chronic inflammatory disease of the nasal cavity or sinuses, which can lead to the growth of soft tissues known as nasal polyps, usually characterized by an increase in eosinophil levels.

According to the Zhitong Finance APP, on January 2, the NMPA official website showed that GSK's IL-5 monoclonal antibody mepolizumab injection (Nucala) has been approved for a new indication, speculated to be for chronic sinusitis with nasal polyps.

big

Chronic sinusitis with nasal polyps is a chronic inflammatory disease of the nasal cavity walls or sinuses, which can lead to the growth of soft tissue called nasal polyps, usually characterized by elevated levels of eosinophils. The resulting swelling can grow in both nostrils (bilateral), greatly impacting patients due to various symptoms including nasal congestion, loss of smell, facial pressure, and nasal discharge. For severe cases, surgical treatment may be necessary. However, polyps have a strong tendency to recur, often leading to repeat surgeries.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment